Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

Rhea-AI Summary

Aethlon Medical (Nasdaq: AEMD) will release fiscal third quarter results for the period ended December 31, 2025 at 4:15 p.m. ET on February 12, 2026. Management will host a conference call at 4:30 p.m. ET the same day to review results and corporate developments.

Registered participants receive dial-in details; a replay will be available about one hour after the call through March 12, 2026 with conference ID 3024961.

News Market Reaction – AEMD

-3.86%

1 alert

-3.86% Session close to close

$2.27M Market Cap

0.7x Rel. Volume

In the Feb 4 session, AEMD declined 3.86%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Aethlon’s fiscal Q3 results on February 12, 2026 and a foll...

Analysis

This announcement sets the timetable for Aethlon’s fiscal Q3 results on February 12, 2026 and a follow-on conference call. Historically, similar earnings-date notices produced only modest share moves, suggesting they function mainly as logistical updates. Investors may focus on forthcoming details about cash, operating expenses, and clinical progress, as well as any updates relative to recent financings and regulatory filings once the full results are released.

Key Figures

Quarter end date: December 31, 2025 Earnings release time: 4:15 p.m. ET Conference call time: 4:30 p.m. ET +5 more

8 metrics

Quarter end date December 31, 2025 Fiscal third quarter reporting period

Earnings release time 4:15 p.m. ET Fiscal Q3 2025 results on February 12, 2026

Conference call time 4:30 p.m. ET Fiscal Q3 2025 conference call on February 12, 2026

US toll-free dial-in 1-844-836-8741 Participant dial-in for live conference call

International dial-in 1-412-317-5442 International participant dial-in for live call

Replay end date March 12, 2026 Replay available until this date

Replay US/Canada dial-in 1-855-669-9658 Access number for recording of the call

Replay conference ID 3024961 ID required to access conference replay

Previous Conferences,earnings date Reports

1 past event · Latest: Nov 07 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 07	Earnings date notice	Neutral	-1.6%	Announced Q2 results release timing and post-close conference call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings-date conference scheduling news was followed by a modest negative move, suggesting no strong positive trading bias around such notices.

Recent Company History

Over the last few months, Aethlon Medical has mixed catalysts, including a December 2025 private placement, Long COVID preclinical data, fiscal Q2 results, and early oncology trial signals. For the specific tag "conferences,earnings date", the November 7, 2025 notice about releasing Q2 results and hosting a call led to a -1.64% move. Today’s Q3 earnings-date announcement fits this pattern of routine scheduling updates around quarterly results and conference calls.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026.

Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.

Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034a255186. Please note that registered participants will receive their dial-in number upon registration.

Interested parties without internet access or unable to pre-register may dial in by calling:

PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

All callers should ask for the Aethlon Medical, Inc. conference call.

A replay of the call will be available approximately one hour after the end of the call through March 12, 2026. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 3024961.

About Aethlon and the Hemopurifier^®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Additional information can be found at www.AethlonMedical.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Risks and uncertainties include, but are not limited to, clinical trial outcomes, regulatory approvals, the ability to obtain additional financing, and market acceptance of the Company's products, as more fully described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com 

 

View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-fiscal-third-quarter-financial-results-and-host-conference-call-on-february-12-2026-302678752.html

SOURCE Aethlon Medical, Inc.

FAQ

When will Aethlon Medical (AEMD) release fiscal Q3 2026 results and hold the conference call?

Aethlon Medical will release fiscal Q3 results at 4:15 p.m. ET on February 12, 2026. According to the company, management will host a conference call at 4:30 p.m. ET on the same day to review results and answer questions.

How can investors register for the Aethlon Medical (AEMD) Feb 12, 2026 conference call?

Investors can register online via the provided registration link to receive dial-in details. According to the company, registered participants will receive their unique dial-in number upon registration for the February 12, 2026 call.

What dial-in numbers can participants use for the Aethlon Medical (AEMD) earnings call if they cannot pre-register?

Participants without internet access may dial toll-free 1-844-836-8741 or international 1-412-317-5442. According to the company, callers should ask for the Aethlon Medical conference call to join the Feb 12, 2026 session.

Will a replay of the Aethlon Medical (AEMD) Feb 12, 2026 call be available and how long will it remain accessible?

A replay will be available about one hour after the call and remain accessible through March 12, 2026. According to the company, the replay can be accessed via the website or by dialing the listed replay numbers with conference ID 3024961.

What topics will Aethlon Medical (AEMD) cover during the February 12, 2026 conference call?

The call will review fiscal third quarter financial results and recent corporate developments. According to the company, management will give formal remarks followed by a question-and-answer session for investors and analysts.